Background. Kidney transplantation is regarded as the optimal treatment for pediatric patients with end-stage renal disease. Here, we address a controversial topic in pediatric kidney transplantation by performing a quantitative evaluation of the effect of human leukocyte antigen (HLA) mismatching on the outcomes of pediatric kidney transplantation. Methods. We systematically searched PubMed, EMBASE and the Cochrane Library from their inception to 31 December 2016 for cohort studies assessing the risk ratio (RR) of HLA mismatching on pediatric kidney transplantation. Outcome measures included graft failure, rejection and all-cause mortality. RRs and 95% confidence intervals (CIs) were used as estimates of effect size in random-effect models. Results. Eighteen studies comprising a total of 26 018 pediatric recipients were included in the evaluation. Compared with 0-1 HLA-DR mismatch, 2 mismatches significantly increased the risk of graft failure at 1 year (RR: 1.41, 95% CI: 1.11-1.80), 3 years (RR: 1.28, 95% CI: 1.08-1.52), 5 years (RR: 1.21, 95% CI: 1.04-1.41) and 10 years (RR: 1.30, 95% CI: 1.02-1.67). For HLA-A þ B, the 5-year graft failure risk was higher for 2-4 mismatches compared with 0-1 mismatch (RR: 3.17, 95% CI: 1.20-8.36), but not for 3-4 compared with 0-2 mismatches (RR: 1.49, 95% CI: 0.79-2.80). Conclusions. Based on pooled analysis, HLA-DR and HLA-A þ B are important factors affecting post-transplant outcomes, especially graft failure, in pediatric recipients. Additional randomized controlled trials with higher quality evidence are needed for further investigation.
I N T R O D U C T I O N
Kidney transplantation is recognized as a better treatment choice than dialysis for patients with end-stage renal disease (ESRD) [1] . According to the report of the Global Observatory on Donation and Transplantation (www.transplant-observa tory.org), 80 000 kidney transplantations are performed globally every year [2] . The prevalence of pediatric ESRD has increased markedly over the past few decades. The United States Renal Data System (USRDS) recently reported that 14 per million children develop ESRD, which accounts for 1.3% of all ESRD patients. Up to 72.9% of pediatric ESRD patients eventually undergo kidney replacement [3] .
Human leukocyte antigen (HLA) compatibility is a critical prognostic factor in kidney transplantation [4] . The recent emergence of new, potent immunosuppressive agents and the relatively immature immune systems of pediatric patients have led to organ allocation policies that, although shortening the waiting times, have increased transplantation in children with poorly HLA-matched kidneys [5, 6] . Although extensive cohort studies have investigated the associations between HLA mismatching and the outcomes of pediatric kidney transplantation [4, [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] , the results have been inconsistent. A comprehensive meta-analysis of the available evidence is still lacking.
In this study, we aimed to evaluate the effect of HLA mismatching on the outcomes of pediatric kidney transplants.
M A T E R I A L S A N D M E T H O D S
Our study was conducted in accordance with the Meta-analyses of Observational Studies in Epidemiology (MOOSE) guidelines [23] and Meta-Analyses (PRISMA) statement [24] (Supplementary data, Tables S1 and S2).
Search strategy
We performed a computerized search of published English articles without restriction to region or publication type. Three electronic data sources were searched: PubMed, EMBASE and the Cochrane Library, from the inception of each database to 31 December 2016. Various combinations of Medical Subject Headings and free-text aliases for kidney transplant and HLA were searched (details of the study protocol are described in Supplementary data, Appendix S1). All references listed in the selected articles were carefully screened to identify additional pertinent studies not uncovered in the initial search.
Study selection
We included articles reporting the outcomes of pediatric kidney transplantation with respect to HLA mismatching. Outcome measures were graft failure, rejection and all-cause mortality. The incidence of measured outcomes was defined according to the European Renal Best Practice Transplantation Guidelines and Kidney Disease: Improving Global Outcomes Guidelines [25, 26] . We excluded publications reporting research on adults or animals, in vitro research, studies on irrelevant topics or studies lacking sufficient data (such as reviews, meta-analyses, case reports/case series and technical descriptions). If two reports covered overlapping studies, the study with the larger sample size and/or longer duration was selected. The retrieved titles and abstracts of all publications identified in the initial search were screened by two independent reviewers. The full text of the remaining articles was obtained and assessed to determine whether the data met the inclusion criteria for our meta-analysis. Any discrepancies in study selection were resolved through a team discussion.
Data extraction
Information was extracted from each article by two independent reviewers and entered into standardized Excel forms. Disagreement was resolved by consensus. For all included articles, we extracted publication date, country of origin, sample size, recipient age, recipient sex, donor source, data source, immunotherapy regimen, analyzed HLA subtypes, graft failure events, graft rejection events and mortality rates. The methodological quality of the included studies was described using the Newcastle-Ottawa Scale, which assigns a maximum quality score of 9 points [27] .
Statistical analysis
Risk ratios (RRs) with 95% confidence intervals (CIs) were calculated for dichotomous variables. Risk estimates of the included studies were pooled using DerSimonian-Laird random-effects models. Data were digitized from survival curves using Engauge Digitizer software (http://arohatgi.info/ WebPlotDigitizer/) if the raw data were unavailable. Heterogeneity across studies was assessed using v 2 test and the I 2 statistic. An I 2 value of 0-25% represents insignificant heterogeneity, 26-50% low heterogeneity, 51-75% moderate heterogeneity and >75% high heterogeneity [28, 29] . Sensitivity analysis was conducted to evaluate the stability of our results and to explore the potential source of heterogeneity. Publication bias was assessed with funnel plots and Egger's asymmetry test [30] . Egger's test with a two-sided P < 0.1 was considered to be statistically significant publication bias. A random-effects univariate meta-regression was also performed to explore the heterogeneity. All statistical analyses were performed using STATA software, version 12.0 (StataCorp, College Station, TX, USA).
R E S U L T S

Search results and study characteristics
We retrieved 888 studies from PubMed, 974 from EMBASE and 94 from the Cochrane Library. After selection criteria were applied, 18 [4, [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] cohort studies of 17 publications comprising 26 018 pediatric recipients eligible for analysis were included ( Figure 1 ). Characteristics of the 18 studies are shown in Table 1 . Seventeen studies reported graft failure, three reported rejection and two reported all-cause mortalities with four studies reporting on more than one outcome. Eleven studies [4, [8] [9] [10] [11] [12] [13] [14] [15] provided sufficient data for meta-analysis, whereas the data for the remaining seven studies [7, [16] [17] [18] [19] [20] [21] [22] were reported qualitatively with different statistical methods or parameters.
Graft failure
Seven studies [4, 8, [11] [12] [13] 15] reported data on HLA-DR matching and graft failure at 1 year. Compared with 0-1 mismatches in HLA-DR, 2 mismatches were associated with a significant increase in the risk of graft failure at 1 year (n ¼ 11 748, RR: 1.41, 95% CI: 1.11-1.80, P ¼ 0.006; Figure 2A ). The heterogeneity was moderate (v 2 -test P ¼ 0.003, I
2 ¼ 69.8%). The same seven studies [4, 8, [11] [12] [13] 15 ] also reported data on graft failure at 3 years. Compared with 0-1 mismatches in HLA-DR, 2 mismatches were associated with a significant increase in the risk of graft failure at 3 years (n ¼ 11 748, RR: 1.28, 95% CI: 1.08-1.52, P ¼ 0.004; Figure 2B ). The heterogeneity was also moderate (v 2 -test P ¼ 0.007, I
2 ¼ 66.0%). A significant association was also detected between 0-1 and 2 mismatches for the 5-year graft failure risk (eight studies [4, 8, 11-13, 15, 16] , n ¼ 12 021, RR: 1.21, 95% CI: 1.04-1.41, P ¼ 0.012; Figure 2C ) with moderate heterogeneity (v 2 -test P ¼ 0.002, I
2 ¼ 68.9%). Three studies [4, 10, 16] reported data on graft failure at 10 years, and the results again showed a significant difference between 0-1 and 2 mismatches in HLA-DR (n ¼ 2280, RR: 1.30, 95% CI: 1.02-1.67, P ¼ 0.038; Figure 2D 
¼67.0%).
Given the considerable prognostic benefits of living-donor compared with deceased-donor transplants [31] , we reassessed the effect size estimates of cadaveric donor transplant recipients after excluding the studies of Al-Otaibi et al. [4] and Wafa et al. [16] . However, this had no effect on the pooled outcomes for the 1-, 3-and 5-year graft failure risks (1 year RR: 1.40, 95% CI: 1.09-1.80; 3 years RR: 1.28, 95% CI: 1.06-1.53; 5 years RR: 1.22, 95% CI: 1.04-1.44).
For the HLA-A and HLA-B loci, three studies [9, 13, 16] were analyzed to determine the risk of graft failure after 5 years. Compared with 0-1 mismatches in either HLA-A or HLA-B,
2-4 mismatches gave significantly poorer outcomes, with a pooled RR of 3.17 (n ¼ 628, 95% CI: 1.20-8.36, P ¼ 0.020; Figure 3A ). The heterogeneity was moderate (v 2 -test P ¼ 0.020, I 2 ¼ 74.6%). There was no significant difference between 0-2 and 3-4 mismatches in HLA-A þ B in the 5-year graft failure risk (three studies [13, 14, 16] , n ¼ 576, RR: 1.49, 95% CI: 0.79-2.80, P ¼ 0.216; Figure 3B ). The heterogeneity was relatively high (v 2 -test P ¼ 0.003, I
2 ¼ 82.9%).
Graft rejection
Three studies [7, 17, 18] reported on the effect of HLA mismatching on graft rejection. Birk et al. [18] found no significant differences in chronic rejection among various combinations of HLA-A, -B and -DR mismatches. Vu et al. [7] reported that patients with 1 or 2 HLA-DR mismatches had 1.7-fold higher odds of rejection compared with patients with 0 mismatches (n ¼ 178, 95% CI: 1.1-2.7, P ¼ 0.006). Elshihabi et al. [17] reported that, compared with 0 HLA-DR mismatches, 1 and 2 mismatches increased the odds of first rejection episodes by 1.14-and 1.29-fold, respectively.
All-cause mortality
Two studies [4, 14] reported all-cause mortality events. AlOtaibi et al. [4] reported no significant differences in mortality across various degrees of HLA-DR mismatching in 104 Egyptian pediatric primary renal transplant patients. Similarly, Najarian et al. [14] found no significant effect of HLA-A þ B mismatching on post-transplant survival of 304 American primary pediatric patients.
Sensitivity analyses
Sensitivity analyses were performed using random-effects models. A summary of the results is provided in Supplementary data, Figure S2 . After removal of a duplicate cohort studied by both Opelz and Döhler [15] and Johnson et al. [12] , no associations were found between the number of HLA-DR mismatches and 1-, 3-or 5-year graft failure risks (detailed analyses are shown in Supplementary data, Figure S3 ).
Assessment of heterogeneity
Pooled analysis of the associations between HLA mismatching and graft failure showed a moderate degree of heterogeneity (25% I 2 75%). A random-effects univariate metaregression was performed to explore the potential source of heterogeneity (detailed effect estimates are summarized in Supplementary data, Figure S1 ). The results indicate that ethnicity was significantly associated with graft failure at 5 years (univariate P ¼ 0.047, Figure 4 ) and accounted for 77.41% of the heterogeneity. A subsequent subgroup analysis was performed according to ethnicity (mixed population, North American, Caucasian and Egyptian). Interestingly, however, the heterogeneity was insignificant for each subgroup (I 2 ¼ 0%, Figure 5 ).
Assessment of methodological quality and publication bias
All analyzed studies scored at least 6 on the Newcastle-Ottawa Scale (details of the quality assessment are described in Supplementary data, Table S3 ). Funnel plots were constructed and Egger's tests were performed to evaluate publication bias. Visually H L A m i s m a t c h i n g o n k i d n e y t r a n s p l a n t a t i o n 
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inspected funnel plots are shown in Supplementary data, Figure  S2 . By Egger's test, no evidence of publication bias was found for HLA-DR mismatches and graft failure at 1 year (P ¼ 0.964, Supplementary data, Figure S3A ), 3 years (P ¼ 0.847, Figure S3B ) or 5 years (P ¼ 0.895, Supplementary data, Figure S3C ).
D I S C U S S I O N
This is the first comprehensive meta-analysis to assess the prognostic value of HLA compatibility for the outcomes of pediatric kidney transplantation. We identified and analyzed 18 cohort In addition, we found that 0-1 mismatches in HLA-A þ B resulted in superior overall graft survival at 5 years than did 2-4 mismatches. Few studies have examined the correlation between HLA compatibility and graft rejection or all-cause mortality, and the data are not suitable for pooling analysis. However, the reports from Vu et al. [7] and Elshihabi et al. [17] indicate that HLA-DR mismatching significantly increases the risk of graft rejection.
Human HLA genes are located on chromosome 6 and code for three major HLA class I alleles (HLA-A, -B, -C) and three major HLA class II alleles (HLA-DR, -DQ, -DP). Polymorphisms in HLA, especially the HLA-A, -B and -DR loci, are important biological barriers to successful kidney transplantation [32] . Patients who receive an HLA-mismatched transplant may require higher doses of immunosuppressive agents and more intensive anti-rejection treatment, both of which are related to patient mortality and graft outcomes [4] . However, the importance of HLA compatibility is often minimized owing to the emergence of increasingly potent immunosuppressive treatments [33] . In addition, the benefits of the less-mature immune systems of pediatric patients have resulted in policies that allocate relatively poorly HLA-matched kidneys to children [6, [34] [35] [36] . In many countries, donor-recipient matching at HLA-A and -B loci are not taken into consideration because many cohort studies have reported only minor survival benefit. However, new allocation policies and research in many countries still highlight the importance of HLA-DR compatibility [37, 38] . A series of studies conducted by Doxiadis et al. [39, 40] demonstrated that the influence of HLA-A and -B compatibility disappears when patients receive a HLA-DR-incompatible transplant. Recent European Renal Best Practice Transplantation Guidelines advocate for matching of HLA-A, -B and -DR whenever possible, whereas giving more weight to HLA-DR matching [41] (2 C-Grade Recommendations). Notably, our meta-analysis also indicated a significant association of HLA-DR mismatching with graft failure at 1, 3, 5 and 10 years. Considering the marked difference in the survival of organs from cadaveric donors compared with living donors, we recalculated the statistical estimates of cadaveric donor transplant recipients after excluding the studies of AlOtaibi et al. [4] and Wafa et al. [16] . However, this had no effect on the pooled outcomes for the 1-, 3-and 5-year graft failure rates with different degrees of HLA-DR mismatches. Similar to the findings of other large cohort studies [12, 15] , our analysis implies that HLA-DR matching is important in terms of both donor selection and graft survival in pediatric recipients.
Our analysis also indicated that graft survival at 5 years was better for pediatric recipients with 0-1 mismatches compared with 2-4 mismatches in HLA-A þ B. However, no significant difference was found between 0-2 and 3-4 mismatches, which implied that 2 mismatches of HLA-A þ B may be a dividing point in clinical practice. However, insufficient data [13, 16] was available for meta-analysis to verify the difference between 0 and 1-2 mismatches or between 0-1 and 2 mismatches. Thus, our pooled analysis suggested giving preference to 0-1 mismatches in HLA-A þ B, and further studies are required to identify the pros and cons of 2 mismatches in HLA-A þ B. Besides, a single-center study by El-Husseini et al. [31] [38] also demonstrated superior immunologic graft-survival and acute-rejection outcomes in patients with optimal HLA-A þ B matching in this era of novel immunosuppressants. These results and those of our study imply that HLA-A þ B matching is still an important consideration in pediatric graft recipients.
Despite the paucity of data available for pooled analysis of HLA compatibility and all-cause mortality or graft rejection, the studies by Vu et al. [7] and Elshihabi et al. [17] indicate that HLA-DR mismatching confers an increased risk of graft rejection. The North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) registry study from Elshihabi et al. [17] reported that 1 and 2 HLA-DR mismatches increased the odds of first rejection episodes by 1.14-and 1.29- fold, respectively, compared with 0 mismatches. Similarly, the single-center study conducted by Vu et al. [7] found a 1.7-fold increase in the odds of rejection in pediatric recipients with 1-2 HLA-DR mismatches compared with 0 mismatches. These results reinforce the role of HLA-DR mismatching in the prognosis of pediatric kidney transplant recipients.
The present study has several limitations. First, the absence of randomized controlled trials was the biggest limitation of our meta-analysis. Second, we could not extract multivariable adjusted data from the included studies, which would have superior methodological qualities. Third, ethnic diversity was the main potential source of heterogeneity in this study, probably because of varying HLA polymorphisms in the genetic makeup of the geographically distinct cohorts. Fourth, insufficient evidence was available for us to perform a quantitative analysis to individually address the effects of the HLA-A or -B alleles on graft outcomes. Finally, the available data on the associations of HLA mismatches and other important prognostic parameters (all-cause mortality and graft rejection) are insufficient for pooled quantitative analysis.
C O N C L U S I O N
To our knowledge, this is the first meta-analysis to quantify the prognostic value of HLA mismatching in pediatric kidney transplantation. The pooling analysis indicated a significant association between HLA-DR mismatching and graft failure at 1, 3, 5 and 10 years. This and other cohort studies support the primacy of HLA-DR matching in both donor selection and graft survival. In addition, HLA-A þ B compatibility remains a considerable factor in determining graft outcome, with a recommendation of 0-1 mismatches. Further studies should be conducted to quantify the associations between HLA mismatching and other important prognostic parameters, such as delayed graft function, post-transplant growth concerns and viral infections. Finally, our study was based on observational cohort studies, and randomized controlled trials with higher quality data will be required for further clarification.
S U P P L E M E N T A R Y D A T A
Supplementary data are available online at http://ndt.oxfordjour nals.org
A C K N O W L E D G E M E N T S
We especially thank Huifang Li and Qingmei Yu from the library of Peking University First Hospital, Beijing, China for their active assistance in searching the literature.
A U T H O R S ' C O N T R I B U T I O N S
All authors take responsibility for the integrity of the data and the accuracy of data analysis. Study concept and design was carried out by J.D.; extraction, analysis and interpretation of data by X.S. and R.L.; drafting of the manuscript by X.S.; critical revision of the manuscript by J.D., J.L. and X.Z.; statistical analysis by X.S., R.L., X.X. and J.L.; and technical support by W.H.
F U N D I N G
This study was supported by the National Key Research and Development Program of China (grant No. 2016YFC0901505); the registry study of rare diseases in children; Beijing key laboratory of molecular diagnosis and study on pediatric genetic diseases (BZ0317).
C O N F L I C T O F I N T E R E S T S T A T E M E N T
None declared.
R E F E R E N C E S
